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Neurology
Exercise therapy and cognitive behavioural 
therapy to improve fatigue, daily activity 
performance and quality of life in 
Postpoliomyelitis Syndrome: the protocol of the
Abstract
Background: Postpoliom yelitis Syndrom e (PPS) is a com p lex o f late onset neurom uscu lar sym ptom s w ith  new  
or increased m uscle w eakness and m uscle fatigab ility  as key sym ptom s. Main clin ical com p la ints  are severe 
fatigue, deterioration in functional ab ilities and health related quality  o f life. Rehabilitation m anagem ent is the 
m ainstay o f treatm ent. Tw o  different therapeutic  in terventions m ay be prescribed (1) exercise therapy or (2) 
cogn itive  behavioural therapy (CBT). H ow ever, the ev idence on the effectiveness o f both in terventions is 
lim ited . The prim ary aim o f the FACTS-2-PPS trial is to study the efficacy o f exercise therapy and CBT for 
reducing fatigue and im proving activ ities and quality  o f life in patients w ith  PPS. Add itionally , the working 
m echan ism s, patients' and therap ists' expectations o f and experiences w ith  both in terventions and cost- 
effectiveness w ill be eva luated .
M ethods/Design: A m ulti-centre , s ing le-b linded , random ized  contro lled  trial w ill be co nducted . A sam ple o f 
81 severe ly  fatigued patients w ith  PPS w ill be recru ited from  3 d ifferent un iversity  hosp itals and the ir 
affiliate rehab ilitation  centres. Patients w ill be random ized  to one o f th ree groups i.e. (1) exercise  therap y + 
usual care, (2) CBT + usual care, (3) usual care. A t base line , im m ed iate ly  post-in tervention  and at 3- and 6- 
m onths fo llow -up , fatigue , activ ities, qua lity  o f life and secondary  ou tcom es w ill be assessed. Costs w ill be 
based on a cost q uestionnaire , and statistical analyses on GEE (generalized estim ated equations). A nalysis 
w ill also co nsider m echan ism s o f chang e during therapy. A responsive eva luation  w ill be conducted  to 
m on ito r the im p lem entation  process and to investigate the persp ectives o f patients and therap ists on both 
in terventions.
Discussion: A m ajor strength o f the FACTS-2-PPS study is the use o f a m ixed m ethods design in w h ich  a 
responsive and econom ic evaluation runs parallel to the trial. The results o f this study will generate new  evidence 
for the rehabilitation treatm ent o f persons w ith  PPS.
Trial registration: Dutch Trial Register NTR1371.
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Background
Poliomyelitis anterior acuta is an acute viral disease that 
attacks the anterior horn cells of the spinal cord and the 
motor neurons of the lower brain stem resulting in flac­
cid paresis or paralysis. Usually there is partial and 
sometimes complete recovery from the self-terminating 
disease. However, many people with a history of polio­
myelitis report late onset neuromuscular symptoms and 
a decline in functional abilities. These late symptoms 
are referred to as Postpoliomyelitis Syndrome (PPS) and 
include new or increased muscle weakness, abnormal 
muscle fatigability, generalized fatigue, muscle atrophy, 
muscle and joint pain, muscle cramps and cold intoler­
ance [1].
The prevalence of PPS has been reported from 15% to 
80% of all patients with previous paralytic polio depend­
ing on the criteria applied and population studied [2]. 
Nearly 60% of a sample of Dutch survivors of the 1956 
polio outbreak experience late onset polio sequelae [3]. 
In Western countries, where the large epidemics date 
back to the 1940s and 1950s, many polio survivors are 
now experiencing progressive complaints related to PPS. 
The World Health Organization (WHO) estimates that 
10 to 20 million polio survivors are alive worldwide, and 
some estimates suggest that 4 to 8 million of them may 
develop PPS [4]. Although, the efforts of the Global 
Polio Eradication Initiative of the W H O  initiated in 
1988, led to an enormous reduction in the number of 
acute polio cases globally ever since, polio is still a rele­
vant problem. In  Western Africa and in South Asia 
polio is still endemic and spread of the virus from these 
countries causes new outbreaks in countries that were 
certified as polio free. Therefore, new cases of PPS can 
be anticipated in the coming decades.
Fatigue is one of the most frequent complaints of PPS 
[5-7] and it is typically described as tiredness or lack of 
energy that increases with physical activity and 
decreases with rest [8]. In a study on disability and 
health problems in 76 Dutch patients with PPS, 78% of 
the subjects selected fatigue as their major problem [9]. 
Subjects with PPS experience higher levels of fatigue 
than healthy controls [10,11]. Fatigue has a negative 
impact on activities of daily living and there is evidence 
that post-polio related fatigue is an important factor for 
the reduced health related quality of life (HRQoL) in 
polio survivors [12].
In current practice, rehabilitation management is the 
mainstay of treatment for PPS. Rehabilitation aims to 
improve patients' capacities to perform activities of daily 
living and adapt performance (i.e. actual behaviour) to 
the available capacities. We expect that a reduction of 
the imbalance between patients' capacities and perfor­
mance will lead to a reduction in fatigue and
improvement in activities and HRQoL. There are two 
possible approaches to achieve this goal; exercise ther­
apy and cognitive behavioural therapy (CBT). However, 
evidence to support the effectiveness of either approach 
is still limited.
The insufficient evidence to support exercise consists 
of contradictory and incomplete information in the lit­
erature. On the one hand, PPS patients are advised to 
avoid muscular overuse and intensive training as this 
could worsen symptoms such as muscle weakness and 
fatigue and provoke a further loss of muscular strength
[1]. On the other hand, physically active PPS patients 
were found to have less symptoms of fatigue than 
sedentary patients [13]. It is unclear whether symptoms 
of fatigue are cause or result of physical inactivity. A 
systematic review on exercise therapy for neuromuscular 
diseases included ten studies on muscle strengthening 
exercises and aerobic exercises in PPS of which five 
demonstrated significant positive effects on muscular 
strength and aerobic capacity without generating any 
adverse effects. However, all these studies had to be 
qualified as having insufficient or limited methodological 
quality [14]. This led to the conclusion that there is 
insufficient evidence for the effectiveness of exercise for 
patients with PPS and that future, preferably multi-cen­
tre, studies are needed. A recent study on the short­
term effectiveness of home- and hospital- based aerobic 
exercise showed improvement on fatigue and quality of 
life [15]. However results were not compared with a 
control group and long-term effectiveness was not eval­
uated in this study.
There is broad evidence for the effectiveness of CBT 
in reducing fatigue in chronic fatigue syndrome, fatigued 
post cancer survivors and multiple sclerosis [16-19]. 
However, there are no studies of CBT for fatigue in PPS.
The evidence for a cognitive behavioural approach in 
PPS is currently limited to results from an uncontrolled 
pilot study in which cognitive behavioural strategies are 
incorporated in a comprehensive multidisciplinary reha­
bilitation program [20]. Although significant reductions 
in fatigue symptoms were found, it is unclear whether 
these effects can be ascribed to the cognitive behavioural 
components of the intervention.
We anticipate that exercise therapy and CBT are both 
effective in reducing fatigue and improving activities and 
HRQoL in patients with PPS compared to the usual 
care. The FACTS-2-PPS study aims to give insight in 
the efficacy of both interventions for patients with PPS. 
As secondary outcomes, the working mechanisms, 
patients' and therapists' expectations of and experiences 
with both interventions and cost-effectiveness will be 
evaluated. These aims have led to the following research 
questions:
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(1) Does exercise therapy for patients with PPS 
reduce fatigue and improve activities and HRQoL as 
compared to usual care?
(2) Does CBT for patients with PPS reduce fatigue 
and improve activities and HRQoL as compared to 
usual care?
(3) What are the generic and disease-specific deter­
minants for treatment success of exercise therapy 
and CBT?
(4) What are patients' expectations of and experi­
ences with exercise therapy and CBT?
(5) What is the cost-effectiveness of exercise therapy 
and CBT compared to usual care?
Methods/Design
Study design
A multi-centre, single-blinded randomized controlled 
trial (RCT) with 6 months follow-up will be conducted 
to evaluate the efficacy of exercise therapy and CBT 
compared to usual care in patients with PPS (Figure 1).
To gain insight into patients' expectations and experi­
ences, a responsive evaluation will be conducted. To 
determine the cost-effectiveness, an economic evaluation 
will be conducted alongside this RCT. The study proto­
col was approved by the Medical Ethics Committee of 
the Academic Medical Centre (AMC) and all participat­
ing centres granted approval to participate.
Study population
All patients will be recruited from outpatient clinics of 
the AMC Amsterdam; the University Medical Centre 
Utrecht (UMCU); the University Medical Centre Nijme­
gen (UMCN) or the affiliate rehabilitation centres. Case 
histories are checked to screen for potentially eligible 
patients. Patients willing to give signed consent are evalu­
ated by a physician to check in and exclusion criteria 
(Table 1). The sample size was calculated for this three- 
arm trial based on the comparison treatment (exercise 
therapy or CBT) versus usual care, with equal allocation 
across treatment arms and 4 repeated measurements (at 
entry (pre-treatment), at 4 months (post-treatment), at 3
F ig u re  1 Stu d y design.
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Table 1 In- and exclusion criteria
Inclusion criteria
(1) diagnosis of PPS according to the criteria of March of Dimes [1]
(2) severe perceived fatigue (CIS-fatigue > =  35) [47]
(3) age between 18 and 75 years
(4) life-expectancy longer than one year
(5) walking-ability at least indoors with or without a walking aid
(6) ability to cycle on a cycle ergometer against a load of at least 25 
Watt
Exclusion criteria
(1) use of psychotropic drugs or other psychiatric treatment
(2) clinicaldepression (BDI-PC > 6) [48]
(3) disabling co-morbidity interfering with the intervention programs or 
influencing outcome
parameters (including cardiopulmonary disease, epileptic seizures, 
poorly regulated diabetes mellitus)
(4) respiratory insufficiency (FVC < 50%pred or CO 2 retention) or 
assisted ventilation
(5) cognitive impairment
(6) insufficient mastery of the Dutch language
(7) pregnancy
months follow-up (short-term follow-up) and at 6 
months follow-up (long-term follow-up), respectively), 
with an estimated correlation coefficient of the repeated 
measurements of rho = 0.79 (based on unpublished data 
from a reproducibility study in 37 PPS patients), a clinical 
relevant improvement of 8 points on the CIS-fatigue scale 
(for both treatments) [17] and an estimated standard 
deviation in each treatment group of 9.3. The total sam­
ple size needed to detect this difference on a 5% level of 
significance (two tailed) with a power of 90% was 24 sub­
jects in each group [21]. We expect a drop-out rate of 
maximal 10%, based on a previous trial in this patient 
group [22]. Therefore 81 patients will be recruited. 
Randomization and blinding
Patients will be assigned to the rehabilitation centre that 
is nearest to their home village. Randomization will be 
stratified per centre. Patients fulfilling both inclusion 
and exclusion criteria will be randomized to one of 
three groups: (1) exercise therapy + usual care, (2) CBT 
+ usual care, or (3) usual care. The randomization 
scheme is computer-generated and will be done by 
creating random blocks of sequences with variable block 
sizes of 3 and 6. The investigator who will perform the 
randomization will inform the patient and, in case of 
allocation to exercise therapy or CBT also the therapist 
of the group allocation.
The investigators that are responsible for the inclusion 
will be blinded. Outcomes will be assessed by blinded 
and independent outcome assessors. At the beginning of 
the assessment patients will be instructed not to reveal 
their group allocation to the investigators. To evaluate
the success of blinding, the investigator will be asked at 
each measurement, to guess the treatment assignment 
of the patient, with options 'CBT', 'exercise therapy', 
'usual care only' and 'unknown'. Analyses will be per­
formed blinded for treatment allocation.
Interventions 
Usual care
The patients in the control and intervention groups will 
all receive usual care. Usual care for PPS patients may 
include usage of assistive devices, orthoses, physical 
therapy, and medication. Patients will not be restricted 
in their activities. Co-interventions will be monitored 
throughout the study.
Exercise therapy
Exercise therapy is designed specifically to enhance phy­
sical capacity. The intervention has a duration of 16 
weeks and consists of (1) a home-based aerobic training 
program three times weekly and a (2) supervised group 
training consisting of muscle strengthening and func­
tional exercises once a week. The therapy will be super­
vised by specifically trained physiotherapists. An 
unblinded member of the project group will supervise 
the therapists and perform integrity checks on each 
treatment location.
(1) The home-based training program consists of indi­
vidually tailored aerobic exercise on a cycle ergometer. 
Patients will be supplied with a cycle ergometer, a log 
book with training instructions and a training scheme at 
home. Heart rate will be continuously measured with a 
heart rate monitor. Furthermore, in the log book 
patients will document the number and duration of 
treatment sessions, the training load, perceived exertion 
on the Borg Rated Perceived Exertion Scale [23] and 
possible complaints after the training session. Training 
intensity will be gradually increased from 60% of the 
Heart Rate Reserve (HRR) to 70% HRR, in accordance 
with the American College of Sports Medicine guide­
lines for aerobic training in healthy adults [24] and per­
sons with chronic diseases and disabilities [25]. The 
duration of the training sessions will gradually be 
increased from 20 to 30 minutes per session and ses­
sions are divided into prescribed exercise bouts which 
are interspersed with short rest periods of unloaded 
cycling. The duration of exercise bouts will be gradually 
increased from 2 minutes at the start of the program to 
13 minutes at the end of the program.
Warming-up and cooling-down consists of 5 minutes 
unloaded cycling. Feasibility of the training schemes is 
weekly checked by one of the therapists by reading out 
the heart rate monitors and checking the log books. 
When necessary, adjustments to the training schemes 
will be made.
(2) The supervised group training consists of individu­
ally tailored muscle strengthening exercises and
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functional exercises in 1-hour group sessions. Sessions 
will be divided into a 5-minute warm-up period of aero­
bic exercises, 30 minutes of muscle strengthening, 20 
minutes functional exercises and a 5-minute cool-down 
period. Muscle strengthening exercise selection and 
dosage will be determined by the therapist at a separate 
visit to the treatment location before the start of the 
program. Muscle groups and accompanying exercises 
will be selected based on patients MRC-scores [26] and 
reported problems in daily activities. Exercises are 
selected based on the best expected effects on physical 
functioning.
Muscle groups with MRC scores less then 3 are not 
selected and quadriceps muscles are always selected 
when this muscle group has a MRC score of at least 3. 
Training load will be based on the 1-RM test [27]. In 
the first 4 weeks, training load will be 50% of 1-RM, 
each exercise consists of 3 sets with 2 minutes rest 
between a set and number of repetitions will be 
increased from 8 to 20 during 4 weeks. W hen the 
desired number of repetitions with the current load is 
reached, training load is increased in week 5 and 9 to 
60 and 70% respectively, and the number of repetitions 
is increased in the same manner as prescribed for the 
first 4 weeks [28].
Cognitive behavioural therapy
CBT will be directed at frequently reported perpetuating 
factors of fatigue in slowly progressive neuromuscular 
disorders [29]. They may involve dysfunctional cogni­
tions with respect to the disease itself, to pain and to 
fatigue [30], dysfunctional attention to pain or fatigue 
symptoms, deregulation of sleep [30,31], deregulation of 
physical, social and/or mental activities [30,31], and low 
social support and negative social interactions [32]. For 
each factor a standardized module is available as part of 
the intervention. Because of the variability of relevant 
perpetuating factors in PPS patients, therapy will be cus­
tomized to each individual. To determine which mod­
ules will be necessary, each perpetuating factor will be 
measured with specific questionnaires (Table 2). The 
number of sessions will be determined by the number 
of modules used and will vary between 12 and 16 ses­
sions, each with a duration of 1 hour during a 4 months 
period. Experienced cognitive behavioural therapists will 
treat the patients. The therapists will be trained in the 
protocol and the use of instruments to determine which 
module should be included in the therapy. Role-playing 
is an important part of this training. In the first CBT 
session individualized concrete behavioural goals of the 
therapy are formulated by the patient with help of the 
therapist. These goals are formulated in terms of con­
crete behaviours the patient wants to perform if he is 
not extremely fatigued anymore. Appendix 1 gives an 
overview of cognitive and behavioural techniques that
Table 2 Instrumentation for module selection CBT
Perpetuating factor for Instrum entation 
fatigue
1. Dysfunctionalcognitions Impact of Event Scale [49]
with respect to the disease PictorialRepresentation of Self and 
Illness Measure (PRISM) [50]
Illness Cognitions Questionnaire (ICQ) 
______________________________ [51]__________________________________
2. Dysfunctionalcognitions M edicalOutcom e Study 36-Item Short- 
with respect to pain Form Health Survey (SF-36; domain:
pain) [52]
Daily Observed Pain (DOP) [53]
Pain Catastrophizing Scale (PCS) [54]
3. Dysfunctionalcognitions Self-Efficacy Scale [18]
with respect to fatigue Jacobsen Fatigue Catastrophizing Scale 
______________________________ (J-FCS) [55]___________________________
4. Dysfunctional attention to Illness Management Questionnaire 
fatigue and pain (IMQ) [56]
5. Deregulation of sleep Sickness Impact Profile (SIP; domain:
sleep and rest) [57]
Symptom Checklist-90 (SCL-90; domain: 
sleep) [58]
6. Deregulation of p h y s i c a l C h r o n i c  Fatigue Syndrome-activity 
activities questionnaire (CFS-AQ; domain:
physicalactivity) [59]
7. Deregulation of s o c i a l M e d i c a l O u t c o m e  Study 36-Item Short- 
activities Form Health Survey (SF-36; domain:
social functioning) [52]
Chronic Fatigue Syndrome-activity 
questionnaire (CFS-AQ; domain social 
activity) [59]
Sickness Impact Profile (SIP; domain: 
socialinteraction) [57]
8. Deregulation of m e n t a l C h e c k l i s t  IndividualStrength (CIS; 
activities domain: concentration) [47]
Sickness Impact Profile (SIP; domain: 
alertness/intellectualfunctioning) [57] 
Chronic Fatigue Syndrome-activity 
questionnaire (CFS-AQ; domain: mental)
______________________________ [5 9 __________________________________
9. Low social support and Social Support Inventory-Interactions 
negative socialinteractions (SSL-I_08) [60]
Social Support Inventory-Discrepancies 
(SSL-D_08) [60]
can be used during CBT for each perpetuating factor of 
fatigue.
Compliance and attrition
Compliance will be assessed by recording the number of 
treatment sessions (CBT or group exercise sessions) 
attended and, for the patients randomized to exercise 
therapy, also the total time spent to aerobic exercise on 
the bicycle ergometer at home will be recorded in a log 
book.
Outcomes
Efficacy and working mechanisms
Outcome measures are presented in Table 3. Our pri­
mary outcome measure is fatigue. Additionally, daily 
activity performance and HRQoL will be evaluated. Sec­
ondary outcomes are categorised in accordance with the 
International Classification of Functioning (ICF) [33] on
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the level of body functions, activities and participation 
and personal factors. As potential effect modifiers the 
following parameters will be studied; demographic vari­
ables, main complaints of PPS, disease severity, co-mor­
bidity, serum creatine kinase activity and the ICF 
environmental factors; social support, HRQoL of the 
partner, coping of the partner and caregiver burden. 
Two secondary outcome measures on the level of body 
functions; cardio-respiratory fitness and neuromuscular 
capacity will be described in greater detail. 
Cardio-respiratory fitness
Subjects will perform a submaximal exercise test on a 
cycle ergometer (Lode Corival, Groningen, The Nether­
lands). The test starts with unloaded pedalling for three 
minutes, followed by a 10 Watt increment every single 
minute and will be terminated if one of the following 
occurs: (1) achieving 80% HRR or, (2) pedalling fre­
quency dropping below 60 rpm, or (3) not being able to 
continue the test for any reason. The same workload 
protocol will be applied at the follow-up measurements. 
Throughout the test, gas exchange variables (COSMED 
K4b2, Rome, Italy) and heart rate will be measured con­
tinuously. Cardio-respiratory fitness will be determined 
based on changes in heart rate and gas exchange 
variables.
Neuromuscular capacity
Maximal voluntary contraction (MVC) of the quadriceps 
muscle will be measured isokinetically between 90° and 
30° knee flexion using a fixed dynamometer (Biodex 
System 3, New York, USA). To determine MVC, sub­
jects will perform three maximal-effort knee extensions 
at an angular velocity of 60°/sec. The highest value of 
peak torque (Nm) will be used for the analyses.
In addition, under isometric conditions, voluntary acti­
vation (VA) will be measured with a modified superim­
posed stimulation technique [34]. The quadriceps 
muscle will be electrically stimulated transcutaneously 
with surface electrodes placed over the proximal and 
distal part of the anterior thigh and using a computer­
controlled constant current stimulator (Digitimer DSH7, 
Welwyn garden City, UK). A triplet (pulse train of three 
200 ^s pulses applied at 300 Hz with a supramaximal 
stimulation current) will be superimposed on a 3-4s 
maximal isometric knee extension at 60° knee flexion. 
An identical stimulation will be delivered to the relaxed 
quadriceps muscle to evoke a resting (control) triplet. 
Voluntary activation will be calculated by the following 
formula:
VA (%) = (1 - (superimposed triplet / control triplet)) x 100%
Fatigability of the quadriceps muscle will be deter­
mined by fatiguing the muscle by a series of electrically 
stimulated contractions. The current will be reduced
such that a single tetanus at 150 Hz evokes approxi­
mately 30-50% of maximal isometric strength. A series 
of trains of 50 Hz stimulation (duration 1000 ms, with 
1000 ms between trains) will be applied for a period of 
300 seconds (150 contractions in total). Recovery of fati­
gue will be monitored by applying the same 50 Hz train 
(1000 ms duration) at different times (15 sec up to 3 
min) after the end of the protocol. Changes in force, 
maximal rate of force rise and half relaxation time will 
be determined. These parameters will be expressed as a 
percentage of the values obtained in the first contraction 
of the protocol to correct for differences in muscle 
strength.
Adverse events
All adverse events reported spontaneously by the parti­
cipants or observed by the therapists will be recorded. 
All adverse events will be followed until they have aba­
ted, or until a stable situation has been reached. 
Responsive evaluation
To gain insight into patients' and therapists' expecta­
tions of and experiences with both interventions, a 
responsive evaluation will be conducted [35,36]. Thera­
pists and a subgroup of patients will be interviewed 
about their experiences with the intervention. The selec­
tion of respondents will be based on the criterion of 
''maximum variation" [37]. The interviews are semi­
structured, with open questions guided by a topic list. 
In order to check the topic list three pilot interviews 
will be conducted with patients and one with a partner. 
Then patients engaged in both interventions will be 
interviewed. Additionally focus groups will be organized 
to validate, deepen and broaden the issues in the inter­
views, starting with two homogeneous focus groups 
(converging interests) with patients and partners, and 
two homogenous focus groups with therapists (one per 
intervention). Then all parties will be brought together 
in a heterogeneous (diverging interests) dialogue group 
to exchange views. In the cyclic process data from ear­
lier phases will be used as input for the next phase; this 
hermeneutic dialectic interaction prevents one-sidedness 
and fosters the validation of data [38]. During all phases 
the interviews and focus groups will be tape-recorded, 
transcribed and analyzed. The analysis will focus on the 
recurring issues and concerns of all parties, and the 
comparison of perspectives. Member checks will be held 
to check the credibility of the analysis [37]. In order to 
consult and gain advice from patient representatives 
with PPS the research team will collaborate with the 
Vereniging Spierziekten Nederland (Dutch patient sup­
port group), in all phases of the research process [39]. 
Economic evaluation
Cost-effectiveness and cost-utility will be evaluated from 
a societal perspective. The costs will include direct
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Table 3 Outcome measures and instrumentation
Instrum entation T1 T2 T3 T4
Primary outcom e measures
Fatigue Checklist Individual Strength (CIS; domain: fatigue) [47] X X X X
Daily activity performance Sickness Impact Profile 68
(SIP-68; domains: mobility range, mobility control, socialbehaviour) [61]
X X X X
HRQoL M edicalOutcom e Study 36-Item Short-Form Health Survey (SF-36) [52] X X X X
Secondary outcom e measures
ICF: Body functions
Pain VisualAnalogue Scale (VAS) X X X X
Emotionalstates Profile of Mood States (POMS) [62,63] X X X X
Sleep disturbances Nottingham Health Profile (NHP; domain: sleep) [64] X X X X
Cardio-respiratory fitness Submaximal exercise test with cycle ergometer X X X X
Neuromuscular capacity Fixed dynamometry and electricalstimulation X X X X
ICF: Activities/Participation
Physicalactivity levelin  daily life Activity Monitor (StepWatch, Cyma, Seattle, WA) on 7 consecutive days X X X X
Perceived participation Impact on Participation and Autonomy Questionnaire (IPA) [65] X X X X
FunctionalCapacity Timed-Up-and-Go test (TUG) [66] and 
2-minute walk test (2-MWT) [67]
X X X X
ICF: Personal Factors
Illness cognitions Illness Cognitions Questionnaire (ICQ) [51] X X X X
Coping Coping Inventory for StressfulSituations (CISS-21) [68] X X X X
GeneralSelf Efficacy GeneralSelf Efficacy Scale (ALCOS-16) [69] X X X X
Effect Modifiers
General effect modifiers
Demographic variables (age, gender, education, 
ethnicity, social-economicalstatus)
X
PPS main complaints Polio Problem List (PPL) [9] X X X X
PPS disease severity MedicalResearch Council scale (MRC) [26] X
Co-morbidity Cumulative Illness Rating Scale (CIRS) [70] X X X X
Serum creatine kinase activity Venipuncture X * X X X
ICF: Environmental factors
Socialsupport SocialSupport Inventory (SSL-D) [60] X X X X
HRQoL (partner) M edicalOutcom e Study 36-Item Short-Form Health Survey (SF-36) [52] X X X X
Coping (partner) Coping Inventory for StressfulSituations (CISS-21) [68] X X X X
Caregiver Strain (partner) Caregiver Strain Index (CSI) [71] X X X X
Econom ic evaluation
HRQoL EuroQol-5D [41] X X X X
Resource use Cost diaries X X X X
* In the exercise group two extra blood samples will be obtained at 5 and 10 weeks. 
T1; pre-treatment, T2; post-treatment, T3; short-term follow-up, T4; long-term follow-up.
health care costs of visits to general practitioners, medi­
cal specialists, therapists, medications and assistive 
devices, direct non-health care costs i.e. non-reimbursa- 
ble costs for complementary medicine and over-the- 
counter medication, and indirect, non-health care costs 
of changes in paid and unpaid work. All these data will 
be collected via cost diaries.
Resource use will be valued following the procedures 
outlined by the Dutch Manual of Costing [40]. Where 
standard cost prices are not available, tariffs or
professional fees will be used to estimate costs. The costs 
of medications will be estimated using the prices reported 
by the Royal Dutch Society for Pharmacy. Productivity 
loss costs from paid work will be estimated using both the 
human capital approach and friction cost method. The 
productivity loss costs from unpaid work will be deter­
mined using a shadow price. Cost prices of the interven­
tions will be determined by a bottom-up calculation.
The effect measures used in the economic evaluation 
will be our primary outcome measure fatigue and
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HRQoL measured with the EuroQol-5D [41] at the four 
different tim e m easurem ents. U tilities will be derived 
using the D utch tariffs and used to determ ine quality- 
adjusted life years (QALYs) [42,43].
Statistical Analyses
GEE (generalized estim ated equations) analyses will be 
used to investigate differences in the effects (primary 
and secondary outcom es) betw een bo th  in tervention  
groups and the usual care group and to investigate asso­
ciations between potential effect modifiers and effect of 
in terventions. Data will be analyzed according to the 
in te n tio n - to - tre a t p rincip le . M issing data  will be 
imputed by carrying the last observation forward.
The econom ic evaluation will also be perfo rm ed  
according to the intention-to-treat principle. First, mean 
differences in QALYs will be tested  using param etric 
tests, and uncerta in ty  expressed by 95% confidence 
intervals. Second, we will conduct between-group com ­
parisons of the mean costs for each of the resource use 
categories and total costs. Confidence intervals around 
the mean cost differences will be obtained by a bias-cor­
rected  and accelerated (Bca) boo tstrapping  based on 
5000 replications [44]. Third, the incremental cost-effec­
tiveness ratio (ICER) will be determined by dividing the 
mean difference in total costs by the mean difference in 
effects. Insight into the uncertain ty  around the m ean 
ICER will be obtained by bootstrapping based on 5000 
replications, the generation of cost-effectiveness planes
[45] and cost-effectiveness acceptability curves [46]. Sen­
sitivity analyses involving the m ost im portant cost dri­
vers will be performed in order to assess the robustness 
of the results.
Discussion
In the FACTS-2-PPS study, the efficacy of exercise ther­
apy and CBT in reducing fatigue and improving activ­
ities and HRQoL in patients with PPS will be evaluated 
in  com parison  w ith  usual care. T his study  cap tu res 
some important strengths.
Firstly, the majority of studies on exercise in PPS eval­
uated the effects of strength or aerobic training in PPS 
separately. However, to execute normal every day activ­
ities, m ore in teg ra ted  functional tasks are necessary 
requiring a combination of strength, endurance, flexibil­
ity, balance and coordination. This study evaluates a 
m ulti-com ponen t exercise train ing  in w hich aerobic, 
strength and functional exercises are combined.
Secondly, a lthough  it is w idely recom m ended  th a t 
behavioural adaptation is an im portant component in the 
management of fatigue in PPS, there are no studies con­
firming the effectiveness of this approach. This is the first 
study that will evaluate the efficacy of CBT in reducing 
fatigue in PPS. The treatm ent protocol was developed by 
investigators with broad experience with CBT for chronic
fatigue syndrome and fatigued cancer survivors, and cus­
tomized to the specific aspects of fatigue in PPS.
Thirdly, the long-term follow-up, the broad arsenal of 
outcome measures on different domains of the ICF and 
the inclusion of a responsive evaluation and an eco­
nomic evaluation gives this study a unique mixed m eth­
ods design. Investigating  p a tien t perspectives and 
possible discrepancies between perspectives of patients 
and professionals will help to elaborate strong and weak 
p o in ts  of b o th  in terven tions, w hich in  tu rn  m ight 
explain specific results obtained in the study. Addition­
ally, this mixed m ethods design will facilitate the deci­
sion m aking w ith  resp ec t to  im p lem en ta tion  of the 
results when the interventions turn out to be effective.
However, the study has also som e lim itations. The 
sample size was based on the detection of an approxi­
mately equal effect size of exercise training and CBT in 
comparison to usual care. Detecting differences in effec­
tiveness betw een b o th  in te rv en tio n s w ould requ ire  
m uch larger sample sizes. Furtherm ore, the design of 
this study, will not give insight into the indicators that 
are helpful in decision m aking abou t ta ilo ring  
interventions.
In conclusion, the results of this study will provide 
greater insight on evidence-based treatm ent options for 
PPS. Successful outcome from the study has the poten­
tial to result in reduced fatigue and improved activities 
and quality of life for patients with PPS. Results might 
lead to alterations of existing international guidelines.
Appendix 1: Overview of CBT intervention
Perpetuating factors: dysfunctional cognitions with 
respect to the disease, pain and fatigue
A patient can have dysfunctional cognitions, for example 
unrealistic expectations on prognosis or difficulties with 
the acceptation of the consequences of PPS. M ore fre­
quent are dysfunctional cognitions with respect to fati­
gue and/or pain. By non helping cognitions as 'I can't 
con tro l the  fatigue ' and 'the  fatigue is te rrib le ', the 
patient catastrophizes about fatigue thereby enlarging 
the experience of fatigue. By means of cognitive restruc­
turing (Socratic dialogue and prom pting new self-talk) 
the patient learns to change these non helpful thoughts 
into more helpful one in daily life.
Perpetuating factor: dysfunctional attention to fatigue 
and pain
Many patients are alert to symptoms of fatigue (or pain). 
Persons in th e ir  social env ironm en t ask the pa tien t 
about the fatigue (or pain). Information and explanation 
will be given that the effect of attending to fatigue (or 
pain) sensations is increasing and intensifying these 
symptoms. By daily exercises the patient can learn how 
to shift attention away from fatigue (or pain). Also les­
sening the a tten tion  from  others for these sym ptom s
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will be realized. The p a rtn e r  of the  p a tien t may be 
involved in this module.
Perpetuating factor: deregulation of sleep
An irregular sleep-wake rhythm  can perpetuate fatigue. 
To restore the biologic rhythm, patients will be encour­
aged to  adhere to  fixed bedtim es and w ake-up tim es 
and will be discouraged from sleeping during the day or 
adapt fixed rest period(s).
Perpetuating factors: deregulation of physical, social and 
mental activities
Polio survivors are known to have strong perseverance. 
From  childhood on they w ere learned  to  deny the ir 
sym ptom s in order to  achieve a norm al life. M any of 
them  have difficulties adapting their physical, social and 
mental activities to their decreasing abilities. First, these 
patients will be thought to pace or reduce the am ount 
of activities. Next, graded increase of certain physical, 
social or m ental activities will help the patient to reach 
step by step their set goals.
Perpetuating factors: low social support and negative 
social interactions
Unrealistic expectations or non helpful cognitions about 
the social environment (for example 'why do I not get help 
from others?') can perpetuate fatigue. After explanation, 
the therapist will help to change non helpful cognitions 
and install more realistic expectations toward others in the 
patien t's  social environm ent. The partn er or relevant 
others may be involved in this part of the therapy.
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